C 42 H 48 F 4 N 6 O 12 ,triclinic, P 1 (no. 2), a =9.534(2) Å, b =11.315(2) Å, c =11.327(2) Å, a =97.89(3)°, Source of materialThe title compound was preparedb yh ydrothermal method. A mixture of Zn(NO 3 ) 2 (0.25 mmol), lomefloxacin hydrochloride (LMF)( 0.50 mmol), 1,4-benzene-dicarboxylic acid (1,4-bdc, 0.50 mmol) and water (12 ml) was stirred for 20 min. The mixture was then transferredtoa23mlTeflon-lined autoclave and kept at 443 Kfor 72 hunder autogenous pressure. After the mixture had been allowedtocool to room temperature slowly. The targeted Zn 2+ complex was not synthesized. Colorless single crystals of the title compound suitable for X-ray analysis were obtained from the reaction mixture. DiscussionLomefloxacin( LMF)i sas ynthetic, broad-spectrum fluoroquinolone antibacterial agent. Itwas active against awide variety of aerobic gram-negative and gram-positive bacteria like norfloxacin [1]. Lomefloxacinisone representative of the quinolone family. Ingeneral, quinolones can form supramolecules with other compounds through charge transfer complex formation [2,3]. But there are no reports about crystal structures of LMFor forming supramoleculesw ith other organic molecules. Our interest has been directed toward the synthesis of ametal complex based on LMF. The asymmetric unit of the title compound consists of one LMF, one half of 1,4-benzenedicarboxylic acid and one water molecule. The structure has extensive intermolecular and intramolecular hydrogen bonds that consolidate athree-dimensional network.